The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure
Open accessAbstract
Background: Although empagliflozin was shown to profoundly reduce cardiovascular events in diabetic patients and blunt the decline in cardiac function in nondiabetic mice with established heart failure (HF), the mechanism of action remains unknown. Methods and Results: We treated 2 rodent models of HF with 10 mg/kg per day empagliflozin and measured activation of the NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome in the heart. We show for the first time that beneficial effects of empagliflozin in HF with reduced ejection fraction (HF with reduced ejection fraction [HFrEF]; n=30–34) occur in the absence of changes in circulating ketone bodies, cardiac ketone oxidation, or increased cardiac ATP production. Of note, empagliflozin attenuated activation of the NLRP3 inflammasome and expression of associated markers of sterile inflammation in hearts from mice with HFrEF, implicating reduced cardiac inflammation as a mechanism of empagliflozin that contributes to sustained function in HFrEF in the absence of diabetes mellitus. In addition, we validate that the beneficial cardiac effects of empagliflozin in HF with preserved ejection fraction (HFpEF; n=9–10) are similarly associated with reduced activation of the NLRP3 inflammasome. Lastly, the ability of empagliflozin to reduce inflammation was completely blunted by a calcium (Ca 2+ ) ionophore, suggesting that empagliflozin exerts its benefit upon restoring optimal cytoplasmic Ca 2+ levels in the heart. Conclusions: These data provide evidence that the beneficial cardiac effects of empagliflozin are associated with reduced cardiac inflammation via blunting activation of the NLRP3 inflammasome in a Ca 2+ -dependent manner and hence may be beneficial in treating HF even in the absence of diabetes mellitus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Psaty, B. M., Lumley, T., Furberg, C. D., Schellenbaum, G., Pahor, M., Alderman, M. H., & Weiss, N. S. (2003) · JAMA · doi:10.1001/jama.289.19.2534 · Cited by 1,088
Resolution of in flammation: state of the art, definitions and terms
Serhan, C. N., Brain, S. D., Buckley, C. D., Gilroy, D. W., Haslett, C., O'Neill, L. A. J., Perretti, M., Rossi, A. G., & Wallace, J. L. (2007) · The FASEB Journal · doi:10.1096/fj.06-7227rev · Cited by 1,045
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999
Self-citationCV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Critical role for calcium mobilization in activation of the NLRP3 inflammasome
Murakami, T., Ockinger, J., Yu, J., Byles, V., McColl, A., Hofer, A. M., & Horng, T. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117765109 · Cited by 923
Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907
Blood Pressure Lowering in Type 2 Diabetes: A Systematic Review and Meta-analysis
Emdin, C. A., Rahimi, K., Neal, B., Callender, T., Perkovic, V., & Patel, A. (2015) · JAMA · doi:10.1001/jama.2014.18574 · Cited by 854
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837
Cefalu, W. T., Leiter, L. A., Yoon, K.-H., Arias, P., Niskanen, L., Xie, J., Balis, D. A., Canovatchel, W., & Meininger, G. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60683-2 · Cited by 724
Clustering of metabolic factors and coronary heart disease
Wilson, P. W. F., Kannel, W. B., Silbershatz, H., & D'Agostino, R. B. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.10.1104 · Cited by 712
Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Heise, T., Bizzotto, R., Mari, A., Pieber, T. R., & Muscelli, E. (2016) · Diabetes · doi:10.2337/db15-1356 · Cited by 712
Baartscheer, A., Schumacher, C. A., Wüst, R. C. I., Fiolet, J. W. T., Stienen, G. J. M., Coronel, R., & Zuurbier, C. J. (2017) · Diabetologia · doi:10.1007/s00125-016-4134-x · Cited by 661
Santos-Gallego, C. G., Requena-Ibanez, J. A., San Antonio, R., Ishikawa, K., Watanabe, S., Picatoste, B., Flores, E., Garcia-Ropero, A., Sanz, J., Hajjar, R. J., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.056 · Cited by 651
Grempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D. E., Bakker, R. A., Mark, M., Klein, T., & Eickelmann, P. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01517.x · Cited by 608
Franssen, C., Chen, S., Unger, A., Korkmaz, H. I., De Keulenaer, G. W., Tschöpe, C., Leite-Moreira, A. F., Musters, R., Niessen, H. W. M., Linke, W. A., et al. (2016) · JACC: Heart Failure · doi:10.1016/j.jchf.2015.10.007 · Cited by 597
Chilton, R., Tikkanen, I., Cannon, C. P., Crowe, S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12572 · Cited by 507
Lee, T.-M., Chang, N.-C., & Lin, S.-Z. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.035 · Cited by 504
Bolinder, J., Ljunggren, Ö., Johansson, L., Wilding, J., Langkilde, A. M., Sjöström, C. D., Sugg, J., & Parikh, S. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12189 · Cited by 482
Inflammation – Cause or Consequence of Heart Failure or Both?
Van Linthout, S., & Tschöpe, C. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0337-9 · Cited by 465
Lin, B., Koibuchi, N., Hasegawa, Y., Sueta, D., Toyama, K., Uekawa, K., Ma, M., Nakagawa, T., Kusaka, H., & Kim-Mitsuyama, S. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0148-1 · Cited by 423
Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart
Creemers, E. E., & Pinto, Y. M. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvq308 · Cited by 403
Komoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D., & Pfister, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.250 · Cited by 396
Empagliflozin Increases Cardiac Energy Production in Diabetes
Verma, S., Rawat, S., Ho, K. L., Wagg, C. S., Zhang, L., Teoh, H., Dyck, J. E., Uddin, G. M., Oudit, G. Y., Mayoux, E., et al. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.07.006 · Cited by 386
Self-citationRidderstråle, M., Andersen, K. R., Zeller, C., Kim, G., Woerle, H. J., & Broedl, U. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70120-2 · Cited by 378
Segura, A. M., Frazier, O. H., & Buja, L. M. (2014) · Heart Failure Reviews · doi:10.1007/s10741-012-9365-4 · Cited by 371
Ye, Y., Bajaj, M., Yang, H.-C., Perez-Polo, J. R., & Birnbaum, Y. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6725-2 · Cited by 368
Liu, Y., Lian, K., Zhang, L., Wang, R., Yi, F., Gao, C., Xin, C., Zhu, D., Li, Y., Yan, W., et al. (2014) · Basic Research in Cardiology · doi:10.1007/s00395-014-0415-z · Cited by 321
Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., Takasu, T., Imamura, M., Li, Q., Tomiyama, H., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.05.014 · Cited by 310
Rieg, T., Masuda, T., Gerasimova, M., Mayoux, E., Platt, K., Powell, D. R., Thomson, S. C., Koepsell, H., & Vallon, V. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00518.2013 · Cited by 310
Sattar, N., McLaren, J., Kristensen, S. L., Preiss, D., & McMurray, J. J. (2016) · Diabetologia · doi:10.1007/s00125-016-3956-x · Cited by 309
Vrhovac, I., Balen Eror, D., Klessen, D., Burger, C., Breljak, D., Kraus, O., Radović, N., Jadrijević, S., Aleksic, I., Walles, T., et al. (2015) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-014-1619-7 · Cited by 290
Mechanistic connection between inflammation and fibrosis
Lee, S. B., & Kalluri, R. (2010) · Kidney International · doi:10.1038/ki.2010.418 · Cited by 286
Heise, T., Seewaldt‐Becker, E., Macha, S., Hantel, S., Pinnetti, S., Seman, L., & Woerle, H. J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12073 · Cited by 273
Habibi, J., Aroor, A. R., Sowers, J. R., Jia, G., Hayden, M. R., Garro, M., Barron, B., Mayoux, E., Rector, R. S., Whaley-Connell, A., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0489-z · Cited by 262
Rosenstock, J., Jelaska, A., Zeller, C., Kim, G., Broedl, U. C., Woerle, H. J., & on behalf of the EMPA‐REG BASAL trial investigators (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12503 · Cited by 252
Verma, S., Garg, A., Yan, A. T., Gupta, A. K., Al-Omran, M., Sabongui, A., Teoh, H., Mazer, C. D., & Connelly, K. A. (2016) · Diabetes Care · doi:10.2337/dc16-1312 · Cited by 232
Self-citationSodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport
Mudaliar, S., Polidori, D., Zambrowicz, B., & Henry, R. R. (2015) · Diabetes Care · doi:10.2337/dc15-0642 · Cited by 225
Mustroph, J., Wagemann, O., Lücht, C. M., Trum, M., Hammer, K. P., Sag, C. M., Lebek, S., Tarnowski, D., Reinders, J., Perbellini, F., et al. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12336 · Cited by 225
Empagliflozin directly improves diastolic function in human heart failure
Pabel, S., Wagner, S., Bollenberg, H., Bengel, P., Kovács, Á., Schach, C., Tirilomis, P., Mustroph, J., Renner, A., Gummert, J., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1328 · Cited by 224
Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes
Daniele, G., Xiong, J., Solis-Herrera, C., Merovci, A., Eldor, R., Tripathy, D., DeFronzo, R. A., Norton, L., & Abdul-Ghani, M. (2016) · Diabetes Care · doi:10.2337/dc15-2688 · Cited by 213
Gembardt, F., Bartaun, C., Jarzebska, N., Mayoux, E., Todorov, V. T., Hohenstein, B., & Hugo, C. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00145.2014 · Cited by 189
Leng, W., Ouyang, X., Lei, X., Wu, M., Chen, L., Wu, Q., Deng, W., & Liang, Z. (2016) · Mediators of Inflammation · doi:10.1155/2016/6305735 · Cited by 172
Byrne, N. J., Parajuli, N., Levasseur, J. L., Boisvenue, J., Beker, D. L., Masson, G., Fedak, P. W. M., Verma, S., & Dyck, J. R. B. (2017) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2017.07.003 · Cited by 171
Self-citationDoi, R., Masuyama, T., Yamamoto, K., Doi, Y., Mano, T., Sakata, Y., Ono, K., Kuzuya, T., Hirota, S., Koyama, T., et al. (2000) · Journal of Hypertension · doi:10.1097/00004872-200018010-00016 · Cited by 170
Kusaka, H., Koibuchi, N., Hasegawa, Y., Ogawa, H., & Kim‐Mitsuyama, S. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0473-7 · Cited by 169
Butler, J., Hamo, C. E., Filippatos, G., Pocock, S. J., Bernstein, R. A., Brueckmann, M., Cheung, A. K., George, J. T., Green, J. B., Januzzi, J. L., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.933 · Cited by 164
Self-citationVerma, S., McMurray, J. J. V., & Cherney, D. Z. I. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.1891 · Cited by 158
Self-citationDevelopment of Heart Failure in Chronic Hypertensive Dahl Rats
Klotz, S., Hay, I., Zhang, G., Maurer, M. S., Wang, J., & Burkhoff, D. (2006) · Hypertension · doi:10.1161/01.hyp.0000215579.81408.8e · Cited by 152
Kurosaki, E., & Ogasawara, H. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.04.003 · Cited by 148
The Importance of NLRP3 Inflammasome in Heart Failure
Butts, B., GARY, R. A., Dunbar, S. B., & Butler, J. (2015) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2015.04.014 · Cited by 147
Insights into the contemporary epidemiology and outpatient management of congestive heart failure
McAlister, F. A., Teo, K. K., Taher, M., Montague, T. J., Humen, D. P., Cheung, L. K., Kiaii, M., Yim, R., & Armstrong, P. W. (1999) · American Heart Journal · doi:10.1016/s0002-8703(99)70251-6 · Cited by 144
Engberink, R. O., Frenkel, W. J., van den Bogaard, B., Brewster, L. M., Vogt, L., & van den Born, B. H. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.05122 · Cited by 138
Empagliflozin’s Fuel Hypothesis: Not so Soon
Lopaschuk, G. D., & Verma, S. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.07.018 · Cited by 134
Self-citationTahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., Takasu, T., Imamura, M., Li, Q., Tomiyama, H., et al. (2014) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12223 · Cited by 132
Heise, T., SEMAN, L. J., Macha, S., Jones, P., Marquart, A., Pinnetti, S., Woerle, H. J., & Dugi, K. A. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0030-2 · Cited by 131
Connelly, K. A., Zhang, Y., Visram, A., Advani, A., Batchu, S. N., Desjardins, J., Thai, K., & Gilbert, R. E. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.11.010 · Cited by 126
Type 2 Diabetes and Heart Failure: Challenges and Solutions
Thomas, M. C. (2016) · Current Cardiology Reviews · doi:10.2174/1573403x12666160606120254 · Cited by 117
Macha, S., Mattheus, M., Halabi, A., Pinnetti, S., Woerle, H. J., & Broedl, U. C. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12182 · Cited by 116
Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation
Benetti, E., Mastrocola, R., Vitarelli, G., Cutrìn, J. C., Nigro, D., Chiazza, F., Mayoux, E., Collino, M., & Fantozzi, R. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.235069 · Cited by 104
Sung, M. M., Das, S. K., Levasseur, J., Byrne, N. J., Fung, D., Kim, T. T., Masson, G., Boisvenue, J., Soltys, C.-L., Oudit, G. Y., et al. (2015) · Circulation: Heart Failure · doi:10.1161/circheartfailure.114.001677 · Cited by 102
Self-citationInflammatory Biomarkers in Heart Failure Revisited: Much More than Innocent Bystanders
von Haehling, S., Schefold, J. C., Lainščak, M., Doehner, W., & Anker, S. D. (2009) · Heart Failure Clinics · doi:10.1016/j.hfc.2009.04.001 · Cited by 102
Li, R., Lu, K., Wang, Y., Chen, M., Zhang, F., Shen, H., Yao, D., Gong, K., & Zhang, Z. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.02.021 · Cited by 101
Heise, T., Jordan, J., Wanner, C., Heer, M. A., Macha, S., Mattheus, M., Lund, S. S., Woerle, H. J., & Broedl, U. C. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.09.001 · Cited by 96
Resveratrol improves exercise performance and skeletal muscle oxidative capacity in heart failure
Sung, M. M. Y., Byrne, N. J., Robertson, I. M., Kim, T. T., Samokhvalov, V., Levasseur, J. L., Soltys, C.-L. M., Fung, D., Tyreman, N., Denou, E., et al. (2017) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00455.2016 · Cited by 90
Self-citationSarashina, A., Koiwai, K., SEMAN, L. J., Yamamura, N., Taniguchi, A., Negishi, T., Sesoko, S., Woerle, H. J., & Dugi, K. A. (2012) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-12-rg-082 · Cited by 86
Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat
Yang, C., Chen, Y.-T., Wallace, C. G., Chen, K., Cheng, B., Sung, P., Li, Y., Ko, S., Chang, H., & Yip, H. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.095 · Cited by 83
Shi, X., Verma, S., Yun, J., Brand‐Arzamendi, K., Singh, K. K., Liu, X., Garg, A., Quan, A., & Wen, X. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-3018-9 · Cited by 76
Self-citationFriedrich, C., Metzmann, K., Rose, P. W., Mattheus, M., Pinnetti, S., & Woerle, H. J. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.12.002 · Cited by 67
Abdurrachim, D., Teo, X. Q., Woo, C. C., Chan, W. X., Lalic, J., Lam, C. S. P., & Lee, P. T. H. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13536 · Cited by 67
Brand, T., Macha, S., Mattheus, M., Pinnetti, S., & Woerle, H. J. (2012) · Advances in Therapy · doi:10.1007/s12325-012-0055-3 · Cited by 65
Regulation of levels of IL‐1 mRNA in human fibroblasts
Yamato, K., El-Hajjaoui, Z., & Koeffler, H. P. (1989) · Journal of Cellular Physiology · doi:10.1002/jcp.1041390322 · Cited by 49
Byrne, N. J., Levasseur, J. L., Sung, M. M. Y., Masson, G., Boisvenue, J., Young, M. E., & Dyck, J. R. B. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw051 · Cited by 45
Self-citationDarwesh, A. M., Jamieson, K. L., Wang, C., Samokhvalov, V., & Seubert, J. M. (2018) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2018-0480 · Cited by 40
Self-citationEMPA-REG: Glucose excretion and lipid mobilization – not storage – saves lives
Jørgensen, N. B., Pedersen, J., & Vaag, A. A. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.02.015 · Cited by 10
Cited by
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
Lopaschuk, G. D., & Verma, S. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2020.02.004 · Cited by 894
Self-citationEffects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Vallon, V., & Verma, S. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-095920 · Cited by 516
Self-citationThe NLRP3 inflammasome: contributions to inflammation-related diseases
Chen, Y., Ye, X., Escames, G., Lei, W., Zhang, X., Li, M., Jing, T., Yao, Y., Qiu, Z., Wang, Z., et al. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00462-9 · Cited by 492
Targeting Mitochondria-Inflammation Circuit by β-Hydroxybutyrate Mitigates HFpEF
Deng, Y., Xie, M., Li, Q., Xu, X., Ou, W., Zhang, Y., Xiao, H., Yu, H., Zheng, Y., Liang, Y., et al. (2021) · Circulation Research · doi:10.1161/circresaha.120.317933 · Cited by 409
Metabolic and Signaling Roles of Ketone Bodies in Health and Disease
Puchalska, P., & Crawford, P. A. (2021) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-111120-111518 · Cited by 282
Metadata
- Authors
- Byrne, N. J., Matsumura, N., Maayah, Z. H., Ferdaoussi, M., Takahara, S., Darwesh, A. M., Levasseur, J. L., Jahng, J. W. S., Vos, D., Parajuli, N., El-Kadi, A. O. S., Braam, B., Young, M. E., Verma, S., Light, P. E., Sweeney, G., Seubert, J. M., & Dyck, J. R. B.
- Venue
- Circulation: Heart Failure
- Published
- 2020-01
- Volume
- 13
- Issue
- 1
- Pages
- e006277-e006277
- ISSN
- 1941-3289 (ISSN-L)
- 1941-3297
- OpenAlex
- W3002400028
- Cited by
- 257
- References
- 80
- FWCI
- 19.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.